Patients with ER-α66-positive breast cancer generally respond favorably to endocrine therapy; however, approximately 40% of such cancers do not respond to tamoxifen therapy. A novel variant of ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

Tamoxifen is one of the most commonly used endocrine therapeutic agents for the treatment of estrogen receptor (ER)-positive breast cancer and is classified as a selective ER modulator ...

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...

Tamoxifen (Nolvadex, Soltamox) is the most widely prescribed breast cancer therapy in the world. Some even call it the "backbone" of breast cancer treatment. Even with all that fanfare, tamoxifen ...